M
Matterhorn Biosciences
Develops T cell receptor therapies targeting cancer through MR1T cell technology
About Matterhorn Biosciences
Matterhorn Biosciences GmbH, founded in 2019 by leading scientists from the University of Basel and Versant Ventures, specializes in pioneering MR1T cell therapies for cancer treatment. The company operates in the biotechnology sector, focusing on adoptive cell therapy to target MR1 presented antigens across a broad range of cancers. Matterhorn's MR1T cells are designed to selectively kill cancer cells while sparing healthy tissues, addressing both liquid and solid tumors. The business model revolves around developing and commercializing these advanced therapies, collaborating closely with academic institutions like the University of Basel and Ridgeline to maintain leadership in MR1 directed cancer cell therapy. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their therapeutic products. The primary clients include healthcare providers, research institutions, and pharmaceutical companies seeking innovative cancer treatment solutions.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Employees
- 6
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Cell Therapy, Woman Founder, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2020 | $30M | $120M | Versant Ventures | ↗ |
| SPINOUT✓Other financing | May 2019 | $0 | — | University of Basel | ↗ |
Growth signals
Latest recorded traffic for Matterhorn Biosciences is 200 monthly website visits, down 23.1% over the last three months. Matterhorn Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Matterhorn Biosciences in the Basel ecosystem
The Matterhorn Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Other known investors1 additional known investor
University of Basel
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Matterhorn Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Matterhorn Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











